195 related articles for article (PubMed ID: 38191242)
21. [Expression of NKG2D/MIC in natural killer cell subsets of patients with primary biliary cirrhosis].
Tang Y; Bao W; Yang J; Ding Q
Zhonghua Gan Zang Bing Za Zhi; 2015 Aug; 23(8):574-9. PubMed ID: 26447619
[TBL] [Abstract][Full Text] [Related]
22. Increase of CIK cell efficacy by upregulating cell surface MICA and inhibition of NKG2D ligand shedding in multiple myeloma.
Nwangwu CA; Weiher H; Schmidt-Wolf IGH
Hematol Oncol; 2017 Dec; 35(4):719-725. PubMed ID: 27430430
[TBL] [Abstract][Full Text] [Related]
23. Valproic acid upregulates NKG2D ligand expression through an ERK-dependent mechanism and potentially enhances NK cell-mediated lysis of myeloma.
Wu X; Tao Y; Hou J; Meng X; Shi J
Neoplasia; 2012 Dec; 14(12):1178-89. PubMed ID: 23308050
[TBL] [Abstract][Full Text] [Related]
24. Interferon-gamma down-regulates NKG2D ligand expression and impairs the NKG2D-mediated cytolysis of MHC class I-deficient melanoma by natural killer cells.
Schwinn N; Vokhminova D; Sucker A; Textor S; Striegel S; Moll I; Nausch N; Tuettenberg J; Steinle A; Cerwenka A; Schadendorf D; Paschen A
Int J Cancer; 2009 Apr; 124(7):1594-604. PubMed ID: 19089914
[TBL] [Abstract][Full Text] [Related]
25. Targeting NKG2D/NKG2DL axis in multiple myeloma therapy.
Liu Z; Wang H; Liu H; Ding K; Shen H; Zhao X; Fu R
Cytokine Growth Factor Rev; 2024 Apr; 76():1-11. PubMed ID: 38378397
[TBL] [Abstract][Full Text] [Related]
26. Clinicopathological significance of major histocompatibility complex class I-related chain a and B expression in thyroid cancer.
Xu X; Rao G; Gaffud MJ; Ding HG; Maki G; Klingemann HG; Groh V; Spies T; Caillat-Zucman S; Gattuso P; Plate J; Prinz RA
J Clin Endocrinol Metab; 2006 Jul; 91(7):2704-12. PubMed ID: 16621903
[TBL] [Abstract][Full Text] [Related]
27. Soluble ligands for the NKG2D receptor are released during HIV-1 infection and impair NKG2D expression and cytotoxicity of NK cells.
Matusali G; Tchidjou HK; Pontrelli G; Bernardi S; D'Ettorre G; Vullo V; Buonomini AR; Andreoni M; Santoni A; Cerboni C; Doria M
FASEB J; 2013 Jun; 27(6):2440-50. PubMed ID: 23395909
[TBL] [Abstract][Full Text] [Related]
28. NKG2D Immunoligand rG7S-MICA Enhances NK Cell-mediated Immunosurveillance in Colorectal Carcinoma.
Wang T; Sun F; Wang Y; Jiang J; Pan M; Yuan M; Zhang H; Du X; Hezam K; Song K; Wang M; Zhang J
J Immunother; 2018 Apr; 41(3):109-117. PubMed ID: 29528990
[TBL] [Abstract][Full Text] [Related]
29. Heat shock protein-90 inhibitors increase MHC class I-related chain A and B ligand expression on multiple myeloma cells and their ability to trigger NK cell degranulation.
Fionda C; Soriani A; Malgarini G; Iannitto ML; Santoni A; Cippitelli M
J Immunol; 2009 Oct; 183(7):4385-94. PubMed ID: 19748980
[TBL] [Abstract][Full Text] [Related]
30. Clinical significance of the immunostimulatory MHC class I chain-related molecule A and NKG2D receptor on NK cells in pancreatic cancer.
Duan X; Deng L; Chen X; Lu Y; Zhang Q; Zhang K; Hu Y; Zeng J; Sun W
Med Oncol; 2011 Jun; 28(2):466-74. PubMed ID: 20354827
[TBL] [Abstract][Full Text] [Related]
31. Role of NKG2D in cytokine-induced killer cells against multiple myeloma cells.
Lu X; Zhu A; Cai X; Jia Z; Han W; Ma L; Zhou M; Qian K; Cen L; Chen B
Cancer Biol Ther; 2012 Jun; 13(8):623-9. PubMed ID: 22555808
[TBL] [Abstract][Full Text] [Related]
32. Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate.
Armeanu S; Bitzer M; Lauer UM; Venturelli S; Pathil A; Krusch M; Kaiser S; Jobst J; Smirnow I; Wagner A; Steinle A; Salih HR
Cancer Res; 2005 Jul; 65(14):6321-9. PubMed ID: 16024634
[TBL] [Abstract][Full Text] [Related]
33. Expression and role of MHC class I-related chain in myeloma cells.
Okamoto M; Inaba T; Yamada N; Uchida R; Fuchida SI; Okano A; Shimazaki C; Taniwaki M
Cytotherapy; 2006; 8(5):509-16. PubMed ID: 17050256
[TBL] [Abstract][Full Text] [Related]
34. Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity.
Pende D; Rivera P; Marcenaro S; Chang CC; Biassoni R; Conte R; Kubin M; Cosman D; Ferrone S; Moretta L; Moretta A
Cancer Res; 2002 Nov; 62(21):6178-86. PubMed ID: 12414645
[TBL] [Abstract][Full Text] [Related]
35. MICA/B-targeted antibody promotes NK cell-driven tumor immunity in patients with intrahepatic cholangiocarcinoma.
Oliviero B; Varchetta S; Mele D; Pessino G; Maiello R; Falleni M; Tosi D; Donadon M; Soldani C; Franceschini B; Torzilli G; Piccolo G; Barabino M; Opocher E; Maestri M; Bernuzzi S; Wucherpfennig KW; Mondelli MU; Mantovani S
Oncoimmunology; 2022; 11(1):2035919. PubMed ID: 35223192
[TBL] [Abstract][Full Text] [Related]
36. Hypoxia induced impairment of NK cell cytotoxicity against multiple myeloma can be overcome by IL-2 activation of the NK cells.
Sarkar S; Germeraad WT; Rouschop KM; Steeghs EM; van Gelder M; Bos GM; Wieten L
PLoS One; 2013; 8(5):e64835. PubMed ID: 23724099
[TBL] [Abstract][Full Text] [Related]
37. [Study of NK cells dysfunction in multiple myeloma patients].
Han W; Zhang X; Jia Z; He J; Chao H; Yang J; Xiao R; Lu X
Zhonghua Xue Ye Xue Za Zhi; 2015 Nov; 36(11):922-5. PubMed ID: 26632464
[TBL] [Abstract][Full Text] [Related]
38. Novel role for STAT3 in transcriptional regulation of NK immune cell targeting receptor MICA on cancer cells.
Bedel R; Thiery-Vuillemin A; Grandclement C; Balland J; Remy-Martin JP; Kantelip B; Pallandre JR; Pivot X; Ferrand C; Tiberghien P; Borg C
Cancer Res; 2011 Mar; 71(5):1615-26. PubMed ID: 21257710
[TBL] [Abstract][Full Text] [Related]
39. Functional Characterisation and Analysis of the Soluble NKG2D Ligand Repertoire Detected in Umbilical Cord Blood Plasma.
Cox ST; Danby R; Hernandez D; Laza-Briviesca R; Pearson H; Madrigal JA; Saudemont A
Front Immunol; 2018; 9():1282. PubMed ID: 29963042
[TBL] [Abstract][Full Text] [Related]
40. GAS6/TAM signaling pathway controls MICA expression in multiple myeloma cells.
Kosta A; Mekhloufi A; Lucantonio L; Zingoni A; Soriani A; Cippitelli M; Gismondi A; Fazio F; Petrucci MT; Santoni A; Stabile H; Fionda C
Front Immunol; 2022; 13():942640. PubMed ID: 35967396
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
